Cinnagen
24
0
1
20
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 24 trials
100.0%
+13.4% vs industry average
67%
16 trials in Phase 3/4
15%
3 of 20 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
Role: collaborator
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
Role: lead
Booster Study of SpikoGen COVID-19 Vaccine
Role: collaborator
Australian Phase 2b Study to Assess Effect of Dose Interval on Spikogen Covid-19 Vaccine
Role: collaborator
Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients
Role: lead
Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer
Role: lead
Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine
Role: lead
Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency
Role: lead
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
Role: lead
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Role: lead
Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration
Role: lead
Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis
Role: lead
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
Role: lead
Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years
Role: lead
Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine
Role: lead
Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
Role: lead
Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)
Role: lead
Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran
Role: lead
Study to Demonstrate Non-Inferior Efficacy and Safety of CinnoRA® Versus Humira® for Treatment of Active RA
Role: lead
Safety and Effectiveness Assessment of PeGagen® (Pegfilgrastim) in the Prevention of Chemotherapy-induced FN
Role: lead